Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE PAOLI-BRUNO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1982601159
CMS profile
419826
Location
MEDLEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$120.40

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $120.40 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan Inc. $120.40 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE PAOLI-BRUNO

NPI 1982601159 · CMS profile ID 419826

Allopathic & Osteopathic Physicians / Family Medicine

MEDLEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $120.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $120.4010/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670916157 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $120.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $961,612.31 249
PY2024 Recipient $4,214.80 1
PY2024 Principal investigator $2,148,310.31 277
PY2023 Principal investigator $1,000,560.67 172
PY2022 Recipient $253.00 2
PY2022 Principal investigator $730,831.67 34
PY2021 Recipient $1,654.33 2
PY2021 Principal investigator $437,077.46 64
PY2020 Recipient $2,885.98 3
PY2020 Principal investigator $359,635.45 60
PY2019 Principal investigator $605,972.33 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $4,767.50 11/30/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949782657
Principal investigator 1 PFIZER INC. $4,767.50 11/23/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949782655
Principal investigator 1 PFIZER INC. $4,145.06 11/23/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949782687
Principal investigator 1 GlaxoSmithKline, LLC. $17,945.10 11/18/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 943988845
Principal investigator 1 GlaxoSmithKline, LLC. $12,340.80 11/02/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 943988885
Principal investigator 1 GlaxoSmithKline, LLC. $23,834.70 10/21/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 943988823
Principal investigator 1 GlaxoSmithKline, LLC. $13,718.00 08/29/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 943988857
Principal investigator 1 GlaxoSmithKline, LLC. $15,334.00 08/03/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 943988879
Principal investigator 1 GlaxoSmithKline, LLC. $10,919.00 07/05/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 943988851
Principal investigator 1 Eli Lilly and Company $7,000.00 06/13/2022 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 917822027
Principal investigator 1 Eli Lilly and Company $14,321.00 06/13/2022 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 917825147
Principal investigator 1 GlaxoSmithKline, LLC. $15,221.00 06/01/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 943988863
Recipient Eli Lilly and Company $248.00 05/31/2022 Covered Recipient Physician PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 917812349
Principal investigator 1 Eli Lilly and Company $8,582.00 05/27/2022 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 917822025
Principal investigator 1 Eli Lilly and Company $8,582.00 05/27/2022 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 917825145
Principal investigator 1 PFIZER INC. $14,656.56 05/10/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949749229
Principal investigator 1 GlaxoSmithKline, LLC. $15,242.00 05/04/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 943988827
Principal investigator 1 PFIZER INC. $15,905.58 05/03/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949749457
Principal investigator 1 PFIZER INC. $137,210.50 04/27/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949708271
Principal investigator 1 GlaxoSmithKline, LLC. $23,934.00 04/06/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 943988869
Principal investigator 1 PFIZER INC. $100,916.48 03/15/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949708253
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,851.85 03/15/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 942343605
Principal investigator 1 GlaxoSmithKline, LLC. $22,564.00 03/02/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 943988834
Principal investigator 1 PFIZER INC. $92,168.49 02/23/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949709739
Principal investigator 1 PFIZER INC. $53,346.30 02/15/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949709724
Principal investigator 1 GlaxoSmithKline, LLC. $18,228.00 02/09/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 943988839
Principal investigator 1 PFIZER INC. $32,062.98 02/05/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949711155
Principal investigator 1 Eli Lilly and Company $1,134.00 02/02/2022 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 917822577
Principal investigator 1 Eli Lilly and Company $2,039.00 01/31/2022 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 917825071
Recipient Eli Lilly and Company $5.00 01/26/2022 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 917807089
Principal investigator 1 PFIZER INC. $1,023.80 01/25/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949711141
Principal investigator 1 Eli Lilly and Company $473.00 01/24/2022 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 917825543
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,765.81 01/19/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 942343599
Principal investigator 1 GlaxoSmithKline, LLC. $22,724.00 01/12/2022 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 943988875
Principal investigator 1 Eli Lilly and Company $558.00 01/05/2022 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 917826505
Principal investigator 1 PFIZER INC. $8,549.66 01/04/2022 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949710487